Comparative Pharmacology
Head-to-head clinical analysis: HYDROCHLOROTHIAZIDE INTENSOL versus METAHYDRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCHLOROTHIAZIDE INTENSOL versus METAHYDRIN.
HYDROCHLOROTHIAZIDE INTENSOL vs METAHYDRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits sodium-chloride symporter in distal convoluted tubule, reducing sodium and chloride reabsorption and increasing water excretion.
Metahydrin (trichlormethiazide) is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption and increasing excretion of water, sodium, chloride, and potassium.
25-100 mg orally once daily or in divided doses. Titrate based on response; maximum 200 mg/day.
Oral, 50-100 mg once daily. Maximum 200 mg/day.
None Documented
None Documented
Terminal half-life 6–15 hours (mean ~10 hours); prolonged in renal impairment (creatinine clearance <30 mL/min) and elderly.
18-30 hours (clinically relevant for once-daily dosing in hypertension; prolonged in renal impairment)
Primarily renal (≥95% as unchanged drug); negligible biliary/fecal elimination (<5%).
Renal: 30% (fecal: 70% as unabsorbed drug, primarily biliary elimination; <1% unchanged in urine)
Category A/B
Category C
Thiazide Diuretic
Thiazide Diuretic